Peginterferon Alfa-2b and Ribavirin for the Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites
Top Cited Papers
Open Access
- 27 May 2004
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (22), 2265-2271
- https://doi.org/10.1056/nejmoa032502
Abstract
Several small studies have reported a lower response rate to interferon alfa among black patients with chronic hepatitis C infection than among white patients. The increased prevalence of infection with hepatitis C virus (HCV) genotype 1, which has a lower response rate than other genotypes, has been suggested as the cause.Keywords
This publication has 17 references indexed in Scilit:
- Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis CHepatology, 2003
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than CaucasiansJournal of Viral Hepatitis, 2001
- The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis CGastroenterology, 2000
- Racial differences in responses to therapy with interferon in chronic hepatitis CHepatology, 1999
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- An Algorithm for the Grading of Activity in Chronic Hepatitis CHepatology, 1996
- Reporting results of cancer treatmentCancer, 1981
- The CES-D ScaleApplied Psychological Measurement, 1977